Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline vs Escitalopram in MDD
NCT05950061Phase 3Completed
- Sponsor
- KRL Hospital
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sertraline and Escitalopram oxalate oral solution in major depressive disorder (MDD) (2 arms), sponsored by KRL Hospital. Primary endpoints: Montgomery-Åsberg Depression Rating Scale at 4 months, Clinical Global Impression at 4 months and 4 more. Started Jun 2022; status: completed.
02
Drugs
sertralineEscitalopram oxalate oral solution
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05950061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950061.